Pfizer’s Cardiovascular and Metabolic Diseases Research Unit (CVMED RU) is located in Cambridge, Massachusetts, immersing our outstanding drug discovery scientists to the heart of one of the leading global centers for biomedical research into cardiovascular and metabolic diseases.
Our mission in CVMED has two aims:
- We aspire to discover new medicines which will help to prevent diabetes and to place young, newly diagnosed diabetic patients in remission.
- We seek to discover novel therapies to reduce the impact of cardio-metabolic diseases on life expectancy and quality of life, thereby reducing longer-term risk of cardiovascular and renal diseases.
Our Chief Scientific Officer (CSO)
Morrie J. Birnbaum, M.D., Ph.D.
Chief Scientific Officer, Pfizer Cardiovascular & Metabolic Disease Research Unit
Morrie Birnbaum is Senior Vice President and Chief Scientific Officer, Cardiovascular and Metabolic Disease (CVMED) Research Unit. Prior to joining Pfizer in 2013, Morrie was Professor of Medicine and Associate Dean for Biomedical Core Resources at the Perelman School of Medicine at the University of Pennsylvania, where in 1994 he was appointed the Rhoda and Willard Ware Professor of Diabetes and an Investigator in the Howard Hughes Medical Institute. He earned his B.A., Ph.D. and M.D. degrees from Brown University. He completed his residency at Barnes Hospital in St. Louis, MO, and post-doctoral training at the University of California, San Francisco and at Sloan-Kettering Cancer Institute in the laboratory of the late Ora M. Rosen. Following an associate professorship at Harvard Medical School, Morrie moved to the University of Pennsylvania.
Morrie is Board certified in Internal Medicine and the recipient of numerous distinguished awards, including election to the American Association of Clinical Investigation, the American Association of Physicians, and as a Fellow of the American Association for the Advancement of Science. He has authored more than 200 scientific papers, and served on the Editorial Boards of Journal of Clinical Investigation and Diabetes, the American Diabetes Association Research Policy Committee, and Chaired the NIH Study Selection on Cellular Aspects of Diabetes and Obesity. Morrie is best known for his research in the signals that regulate and integrate metabolic pathways in liver, muscle, and adipose tissue, and how they are disrupted in insulin resistant states."